FIELD: chemistry.
SUBSTANCE: invention relates to a novel compound selected from the group below, or a pharmaceutically acceptable salt thereof, which possess the properties of RIP21 kinase inhibitors. Novel compounds have the formula
.
EFFECT: compounds can be used to treat a disease or disorder selected from uveitis, interleukin-1 converting enzyme associated fever syndrome, dermatitis, acute lung injury, type 2 diabetes mellitus, arthritis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, early-onset inflammatory bowel disease, extraintestinal inflammatory bowel disease, prevention of ischemia reperfusion injury in solid organ transplant, non-alcohol steatohepatitis, alcohol steatohepatitis, autoimmune hepatitis, asthma, graft versus host disease, systemic lupus erythematosus, multiple sclerosis, sarcoidosis, Blau syndrome, early-onset sarcoidosis, Wegner's granulomatosis, and interstitial pulmonary disease.
18 cl, 2 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICALLY ACTIVE COMPOUNDS | 2013 |
|
RU2654942C2 |
| N-(2-CYANO HETEROCYCLYL)PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | 2014 |
|
RU2669922C2 |
| TYROSINE KINASE INHIBITORS | 2006 |
|
RU2408584C2 |
| JAK KINASE-MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF APPLYING THEREOF | 2010 |
|
RU2529019C2 |
| CHEMICAL COMPOUNDS-759 | 2008 |
|
RU2481348C2 |
| IMIDAZOLONYL QUINOLINES AND USE THEREOF AS KINASE ATM INHIBITORS | 2016 |
|
RU2743343C2 |
| PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
| N-SUBSTITUTED DIOXOCYCLOBUTENYLAMINO-3-HYDROXYPICOLINAMIDES SUITABLE AS CCR6 INHIBITORS | 2019 |
|
RU2784831C2 |
| PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS TAM AND MET KINASE INHIBITORS | 2019 |
|
RU2773611C1 |
| 2-PYRAZINONE DERIVATIVES FOR TREATING DISEASES OR CONDITIONS WHERE INHIBITING NEUTROPHIL ELASTASE ACTIVITY IS USEFUL | 2007 |
|
RU2448098C2 |
